Suppression of colitis by adoptive transfer of helminth antigentreated dendritic cells requires interleukin-4 receptor-α signaling

Scientific Reports

Volumn 7, Issue , 2017, Pages

  Matisz, C E ^a   Faz Lopez B ^b   Thomson, E ^a   Al Rajabi, A ^a   Lopes, F ^a   Terrazas, L I ^b   Wang, A ^a   Sharkey, K A ^a,c   McKay, D M ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR ALPHA; LIPOPOLYSACCHARIDE; PARASITE ANTIGEN;

ADOPTIVE TRANSFER; ANIMAL; BIOSYNTHESIS; COLITIS; CYTOLOGY; DENDRITIC CELL; GENE KNOCKOUT; HYMENOLEPIS DIMINUTA; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; IMMUNOMODULATION; IMMUNOPHENOTYPING; IMMUNOTHERAPY; METABOLISM; MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; SPLEEN;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, HELMINTH; BIOMARKERS; COLITIS; DENDRITIC CELLS; GENE KNOCKOUT TECHNIQUES; HYMENOLEPIS DIMINUTA; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IMMUNOPHENOTYPING; IMMUNOTHERAPY; INTERLEUKIN-10; INTERLEUKIN-4; INTERLEUKIN-4 RECEPTOR ALPHA SUBUNIT; LIPOPOLYSACCHARIDES; MICE; SIGNAL TRANSDUCTION; SPLEEN;

EID: 85010069530     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep40631     Document Type: Article

References (59)

1. Strachan, D. P. Hay fever, hygiene, and household size. Brit Med J 299, 1259-1260 (1989).
2. Zaccone, P., Fehervari, Z., Phillips, J. M., Dunne, D. W. & Cooke, A. Parasitic worms and inflammatory diseases. Parasite Immunol 10, 515-523 (2006).
3. Helmby, H. Human helminth therapy to treat inflammatory disorders -where do we stand. BMC Immunol 16, 1-12 (2015).
4. Maizels, R. M. Parasitic helminth infections and the control of human allergic and autoimmune disorders. Clin Microbiol Infect 22, 481-486 (2016).
5. Hang, L. et al. Heligmosomoides polygyrus bakeri infection activates colonic Foxp3+ T cells enhancing their capacity to prevent colitis. J Immunol 191, 1927-1934 (2013).
6. Blum, A. M. et al. Heligmosomoides polygyrus bakeri induces tolerogenic dendritic cells that block colitis and prevent antigenspecific gut T cell responses. J Immunol 189, 2512-2520 (2012).
7. Hunter, M. M., Wang, A., Hirota, C. L. & McKay, D. M. Neutralizing anti-IL-10 antibody blocks the protective effect of tapeworm infection in a murine model of chemically induced arthritis. J Immunol 174, 7368-7375 (2005).
8. Summers, R. W., Elliott, D. E. & Urban, J. F. Trichuris suis therapy for active ulcerative colitis: A randomized controlled trial. Gastroenterology 128, 825-832 (2005).
9. Motomura, Y. et al. Helminth antigen-based strategy to ameliorate inflammation in an experimental model of colitis. Clin Exp Immunol 155, 88-95 (2009).
10. Correale, J. & Farez, M. Helminth antigens modulate immune responses in cells from multiple sclerosis patients through TLR2-dependent mechanisms. J Immunol 183, 5999-6012 (2009).
11. Carranza, F. et al. Helminth antigens enable CpG-Activated dendritic cells to inhibit the symptoms of collagen-induced arthritis through Foxp3+ regulatory T cells. PLoS One 7, e40356 (2012).
12. Sofronic-Milosavljevic, L. J. et al. Application of dendritic cells stimulated with Trichinella spiralis excretory-secretory antigens alleviates experimental autoimmune encephalomyelitis. Med Microbiol Immunol 202, 239-249 (2013).
13. Hsu, F. J. et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2, 52-58 (1996).
14. Morse, M. A. et al. A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer. Ann Surg 258, 879-886 (2013).
15. Garcia, F. et al. A therapeutic dendritic cell-based vaccine for HIV-1 infection. J Infect Dis 203, 473-478 (2011).
16. Hasselblatt, P. et al. Remission of refractory Crohn's disease by high-dose cyclophosphamide and autologous peripheral blood stem cell transplantation. Aliment Pharmacol Ther 36, 725-735 (2012).
17. Forbes, G. M. et al. A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn's disease refractory to biologic therapy. Clin Gastroenterol Hepatol 12, 64-71 (2014).
18. Ciccocioppo, R. et al. Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease. Gut 60, 788-798 (2011).
19. de la Portilla, F. et al. Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn's disease: Results from a multicenter phase I/IIa clinical trial. Int J Colorectal Dis 28, 313-323 (2013).
20. Matisz, C. E. et al. Adoptive transfer of helminth antigen-pulsed dendritic cells protects against the development of experimental colitis in mice. Eur J Immunol 45, 3126-3139 (2015).
21. Cook, P. C. et al. Alternatively activated dendritic cells regulate CD4+ T-cell polarization in vitro and in vivo. Proc Natl Acad Sci USA 109, 9977-9982 (2012).
22. Gordon, S. Alternative activation of macrophages. Nat Rev Immunol 3, 23-35 (2003).
23. Maroof, A. et al. Interleukin-4 can induce interleukin-4 production in dendritic cells. Immunol 117, 271-279 (2006).
24. Liu, L., Rich, B. E., Inobe, J., Chen, W. & Weiner, H. L. Induction of Th2 cell differentiation in the primary immune response: Dendritic cells isolated from adherent cell culture treated with IL-10 prime naive CD4+ T cells to secrete IL-4. Int Immunol 10, 1017-1026 (1998).
25. Boks, M. A. et al. IL-10-generated tolerogenic dendritic cells are optimal for functional regulatory T cell induction-A comparative study of human clinical-Applicable DC. Clin Immunol 142, 332-342 (2012).
26. Leung, G. et al. Cryopreserved IL-4-Treated macrophages attenuate murine colitis in an integrin β 7-dependent manner. Mol Med 21, 924-936 (2015).
27. Yao, Y., Li, W., Kaplan, M. H. & Chang, C. H. Interleukin (IL)-4 inhibits IL-10 to promote IL-12 production by dendritic cells. J Exp Med 201, 1899-1903 (2005).
28. Keely, S. et al. Contribution of epithelial innate immunity to systemic protection afforded by prolyl hydroxylase inhibition in murine colitis. Mucosal Immunol 7, 114-123 (2014).
29. Anthony, R. M., Rutitzky, L. I., Urban, J. F. (Jr.), Stadecker, M. J. & Gause, W. C. Protective immune mechanisms in helminth infection. Nat Rev Immunol 7, 975-987 (2007).
30. Lopes, F. et al. Helminth regulation of immunity: A three-pronged approach to treat colitis. Inflamm Bowel Dis 10, 2499-2512 (2016).
31. Allen, J. E. & Maizels, R. M. Diversity and dialogue in immunity to helminths. Nat Rev Immunol 11, 375-388 (2011).
32. Ma, Y. L. et al. IL-4-producing dendritic cells induced during Schistosoma japonica infection promote Th2 cells via IL-4-dependent pathway. J Immunol 195, 3769-3780 (2015).
33. van Panhuys, N. et al. Basophils are the major producers of IL-4 during primary helminth infection. J Immunol 186, 2719-2728 (2011).
34. Connor, L. M., Tang, S. C., Camberis, M., Le Gros, G. & Ronchese, F. Helminth-conditioned dendritic cells prime CD4+ T cells to IL-4 production in vivo. J Immunol 193, 2709-2717 (2014).
35. Dowling, D. J. et al. Ascaris lumbricoides pseudocoelomic body fluid induces a partially activated dendritic cell phenotype with Th2 promoting ability in vivo. Int J Parasitol 41, 255-261 (2011).
36. Falcon, C. et al. Excretory-secretory products (ESP) from Fasciola hepatica induce tolerogenic properties in myeloid dendritic cells. Vet Immunol Immunopathol 137, 36-46 (2010).
37. McKay, D. M. & Khan, W. I. STAT-6 is an absolute requirement for murine rejection of Hymenolepis diminuta. J Parasitol 89, 188-189 (2003).
38. Hunter, M. M., Wang, A. & McKay, D. M. Helminth infection enhances disease in a murine TH2 model of colitis. Gastroenterology 132, 1320-1330 (2007).
39. Reyes, J. L. et al. Splenic B cells from Hymenolepis diminuta-infected mice ameliorate colitis independent of T cells and via cooperation with macrophages. J Immunol 194, 364-378 (2015).
40. Harris, D. P., Goodrich, S., Mohrs, K., Mohrs, M. & Lund, F. E. The development of IL-4-producing B cells (B effector 2 cells) Is controlled by IL-4, IL-4 receptor, and Th2 cells. J Immunol 175, 7103-7107 (2005).
41. Noben-Trauth, N., Hu-Li, J. & Paul, W. E. IL-4 secreted from individual naive CD4+ T cells acts in an autocrine manner to induce Th2 differentiation. Eur J Immunol 32, 1428-1433 (2002).
42. Liu, Z., Liu, Q., Hamed, H., Anthony, R. M., Foster, A., Finkelman, F. D., Urban (Jr)., J. F. & Gause, W. C. IL-2 and autocrine IL-4 drive the in vivo development of antigen-specific Th2 T cells elicited by nematode parasites. J Immunol 174, 2242-2249 (2005).
43. Hogaboam, C. M. et al. Therapeutic effects of interleukin-4 gene transfer in experimental inflammatory bowel disease. J Clin Invest 100, 2766-2776 (1997).
44. Xiong, J. et al. Effects of interleukin-4 or interleukin-10 gene therapy on trinitrobenzenesulfonic acid-induced murine colitis. BMC Gastroenterol 13, 165-171 (2013).
45. Gandhi, N. A. et al. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov 15, 35-50 (2016).
46. Neurath, M. F., Finotto, S. & Glimcher, L. H. The role of Th1/Th2 polarization in mucosal immunity. Nat Med 8, 567-573 (2002).
47. Abbas, A. K., Murphy, K. M. & Sher, A. Funcional diversity of helper T lymphocytes. Nature 383, 787-793 (1996).
48. Balic, A., Harcus, Y. M., Taylor, M. D., Brombacher, F. & Maizels, R. M. IL-4R signaling is required to induce IL-10 for the establishment of T(h)2 dominance. Int Immunol 18, 1421-1431 (2006).
49. Jang, J. C. & Nair, M. G. Alternatively activated macrophages revisited: New insights into the regulation of immunity, inflammation and metabolic function following parasite infection. Curr Immunol Rev 9, 147-156 (2013).
50. Leung, G., Wang, A., Fernando, M., Phan, V. C. & McKay, D. M. Bone marrow-derived alternatively activated macrophages reduce colitis without promoting fibrosis: Participation of IL-10. Am J Physiol Gastrointest Liver Physiol 304, G781-G792 (2013).
51. Hunter, M. M. et al. In vitro-derived alternatively activated macrophages reduce colonic inflammation in mice. Gastroenterology 138, 1395-1405 (2010).
52. Gobert, A. P. et al. Protective role of arginase in a mouse model of colitis. J Immunol 173, 2109-2117 (2004).
53. Weisser, S. B. et al. Arginase activity in alternatively activated macrophages protects PI3Kp110d deficient mice from dextran sodium sulfate induced intestinal inflammation. Eur J Immunol 44, 3353-3367 (2014).
54. Campbell, L., Saville, C. R., P. J., M., Cruickshank, S. M. & Hardman, M. J. Local arginase 1 activity is required for cutaneous wound healing. J Invest Dermatol 133, 2461-2470 (2013).
55. Dzik, J. M. Evolutionary roots of arginase expression and regulation. Front Immunol 5, 1-11 (2014).
56. van Liempt, E. et al. Schistosoma mansoni soluble egg antigens are internalized by human dendritic cells through multiple C-Type lectins and suppress TLR-induced dendritic cell activation. Mol Immunol 44, 2605-2615 (2007).
57. Goodridge, H. S. et al. Immunomodulation via novel use of TLR4 by the filarial nematode phosphorylcholine-containing secreted product, ES-62. J Immunol 174, 284-293 (2005).
58. Esser-von Bieren, J. et al. Immune antibodies and helminth products drive CXCR2-dependent macrophage-myofibroblast crosstalk to promote intestinal repair. PLoS Pathog 11, e1004778 (2015).
59. Johnston, M. J. et al. Extracts of the rat tapeworm, Hymenolepis diminuta, suppress macrophage activation in vitro and alleviate chemically induced colitis in mice. Infect Immun 78, 1364-1375 (2010).